24/7 Market News – (NASDAQ: REVB) Revelation Biosciences Inc. Shares are rallying this morning on over 30,000 trades as the company announced completion of dosing for the phase 1 study back on June 13th.

$1.52 shares are up sharply over 142% on more than 6.7 million shares in volume. The company’s previous highest volume day was around 33 million shares and a 52-week high of $11.29.

[mstock id=”73007″ asset=”revb”]

Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis

-Data anticipated in Q3 2022-

SAN DIEGO, June 13, 2022 (GLOBE NEWSWIRE) — Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today announced that it has completed enrollment and dosing of its Phase 1b CLEAR clinical study to evaluate safety and efficacy of intranasal REVTx-99b for the treatment of allergic rhinitis.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist